Product Information
POTASSIUM CITRATE ER 10 MEQ TB is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.1752 per EA under NDC 16571086501. Its NADAC has been published 69 times since Jun 11, 2025.
FDA first approved this application on Jun 8, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
1080 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571086501
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
POTASSIUM CITRATEApproval Type
Generic (ANDA)
FDA Application
ANDA077440FDA Approved
6/8/2006
TE Code
AB
On Market Since
12/15/2024
Pharmacological Classes
Price Statistics
The NADAC for POTASSIUM CITRATE ER 10 MEQ TB has been published 69 times since Jun 11, 2025, and over the history we have for it it has declined 20.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1752 per EA |
|---|---|
| All-time high | $0.2205 (Jun 11, 2025) |
| All-time low | $0.1666 (Sep 17, 2025) |
| 52-week high | $0.1813 |
| 52-week low | $0.1666 |
| Median price | $0.1785 |
| Average price | $0.1809 |
| Largest weekly change | -10.5% (Jul 23, 2025) |
| Weeks tracked | 69 |
| Tracking since | Jun 11, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the potassium citrate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
potassium citrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-coagulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of POTASSIUM CITRATE ER 10 MEQ TB?
The current National Average Drug Acquisition Cost (NADAC) for POTASSIUM CITRATE ER 10 MEQ TB, manufactured by Rising Pharma Holdings Inc., is $0.1752 per EA (NDC 16571086501), effective Sep 30, 2026.
How has the price of POTASSIUM CITRATE ER 10 MEQ TB changed over time?
Over the history we have for it, the NADAC for POTASSIUM CITRATE ER 10 MEQ TB has declined 20.6%. It has been tracked across 69 weekly CMS publications since Jun 11, 2025.
What are the highest and lowest recorded NADAC prices for POTASSIUM CITRATE ER 10 MEQ TB?
Since Jun 11, 2025, the NADAC for POTASSIUM CITRATE ER 10 MEQ TB has ranged from a low of $0.1666 (Sep 17, 2025) to a high of $0.2205 (Jun 11, 2025), with a median of $0.1785 per EA.
Are there cheaper alternatives to POTASSIUM CITRATE ER 10 MEQ TB?
No other NADAC-published product currently shares the active ingredient and strength of POTASSIUM CITRATE ER 10 MEQ TB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures POTASSIUM CITRATE ER 10 MEQ TB?
POTASSIUM CITRATE ER 10 MEQ TB (NDC 16571086501) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.